Comprehensive Management of High-risk PopuLatIon for Stroke Based on Social Network

COmprehensive Management of High-risk PopuLatIon for Stroke bAsed oN soCial nEtwork: A Multicenter Randomized Clinical Trial

The purpose of this study is to evaluate the effectiveness of social network in improving drug compliance and risk factors control rate of stroke high-risk population after discharge.

Stroke is the leading cause of death among residents in China, with the characteristics of high morbidity, high mortality, high disability rate, high recurrence rate and so on, which brings huge economic burden to the patients' families and society. Strengthening the comprehensive management of the high-risk population of stroke, improving the medication compliance of patients and the control rate of stroke risk factors play a key role in reducing stroke recurrence.

This study is a multicenter, prospective, randomized, single-blind study, which aims to use the tool of WeChat Mini Programs to realize the post-hospital follow-up management of the high-risk population of stroke. The follow-up time is 12 months. The main measurement result was the change of patients' medication compliance after comprehensive management.

Inclusion Criteria:

• Age ≥18 years.
• Hospitalized patients at high risk of stroke are those who have at least three of the following risk factors: hypertension, dyslipidemia, diabetes, atrial fibrillation/valvular disease, smoking history, overweight/obesity, physical inactivity, or family stroke history; or those with a history of prior transient ischemic attack (TIA) or stroke.12
• modified Rankin Scale (mRS) score ≤2.
• Smartphone/WeChat access (patient or caregiver).
• Informed consent obtained.
• Active long-term therapy: ≥1 medication (antihypertensive, hypoglycemic, lipid-lowering, anticoagulant, antiplatelet).

Exclusion Criteria:

• Inability to operate smartphones (patient or caregiver).
• Comorbidities potentially confounding outcome assessments, including Advanced malignancies (life expectancy <12 months); Documented dementia; Severe psychiatric disorders (e.g., schizophrenia, major depressive disorder).
• Residence in areas with unreliable internet access.
• Concurrent participation in other clinical trials.
• Any condition deemed by investigators to preclude safe trial participation.